Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation
Status:
Withdrawn
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Suicide is a major crisis worldwide with rates projected to continue to increase. There is
currently a dearth of novel pharmacologic treatment options for suicide available on the
market. The endocannabinoid system has been recently shown to be associated with mood
disorders including suicidality. The aim of the study is to determine whether treatment with
Nabilone is capable of reducing suicidal ideation in adults after 3 days.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston